Brief: TRACON Pharmaceuticals Provides Update On Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation To Continue Trial As Planned
03/04/2024 13:29
April 3 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS PROVIDES UPDATE ON ONGOING ENVASARC
PHASE
2 PIVOTAL TRIAL FOLLOWING INDEPENDENT DATA MONITORING COMMITTEE
RECOMMENDATION TO CONTINUE THE TRIAL AS PLANNED
* TRACON PHARMACEUTICALS INC: FINAL DATA FROM ENVASARC
PHASE 2
PIVOTAL TRIAL EXPECTED IN Q3 OF 2024.
Source text for Eikon: ID:nGNX5DLcHK
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants